
    
      This is a non-randomized pauci-centre, open-label phase II study. The treatment will consist
      in a chemotherapy by FOLFOX and nab-paclitaxel following modalities determined in the Brown
      University Phase I study.

      In neoadjuvant setting : 3 months of treatment

      Main criteria of Withdraw of the treatment: in case of tumor progression, non acceptable
      toxicity, or patient decision.
    
  